Antitumor activity of SGN-CD70A in CTCL PDX mice. The body weight (A) and the survival (B) of mice treated with PBS, or SGN-CD70A at 100 or 300 ug/kg in the dose-finding trial. The cfDNA concentration (C) and the tumor volume (D) in mice treated with PBS, or SGN-CD70A at 100 or 300 ug/kg (n = 4 per group). NSG mice were implanted with PRS-1 primary tumor cells subcutaneously at the right flank on day 0. On day 7, mice in each group were administered intraperitoneally a single dose of PBS, 100 or 300 μg/kg of SGN-CD70A (SGN70A100 and SGN70A300). The tumor volume and cfDNA were presented as mean ± SEM and statistically analyzed by an unpaired t test with a 2-tailed P value. P < .05 represents as a significant difference. The survival curves were generated by the Kaplan-Meier method and analyzed by the Mantel-Cox test.